Marchesini G, Zoli M, Angiolini A, Feliciangeli G, Santoro A, Ferroni P, Zanetti A R
Nephron. 1981;29(1-2):44-8. doi: 10.1159/000182237.
To assess the relevance of HBe/anti-HBe system and DNA polymerase activity in patients on regular dialysis treatment, we prospectively studied 38 patients on haemodialysis, who were chronic carriers of HBs Ag (range 6-66 months), and 26 HBs Ag negative dialysis patients as controls. HBe Ag was present in 74%, DNA polymerase in 60%, and anti-HBe in 13% of HBs Ag positive patients. After a mean follow-up of 23.5 months, only 2 patients, who had been HBe Ag positive, had cleared HBs Ag, and 1 of them had turned to anti HBs positivity. Among the patients who were still HBs Ag positive, only 1 had lost HBe Ag, without developing anti-HBe. Throughout the study, SGOT and SGPT levels were significantly raised in HB virus carriers as compared to controls. In the HBs Ag positive group, the presence of HBe Ag and/or DNA polymerase characterized a subgroup with the most striking abnormalities in enzyme levels. The caused of death in the HBs Ag positive group were not related to liver disease. Viral replication usually takes place in HB virus carrier state, and the underlying liver disease, are not major problems at present in patients on chronic haemodialysis.
为评估HBe/抗-HBe系统及DNA聚合酶活性在规律透析治疗患者中的相关性,我们前瞻性研究了38例慢性乙肝表面抗原(HBs Ag)携带者(携带时间6 - 66个月)的血液透析患者,并将26例HBs Ag阴性的透析患者作为对照。在HBs Ag阳性患者中,74%存在HBe抗原,60%存在DNA聚合酶,13%存在抗-HBe。平均随访23.5个月后,仅有2例曾为HBe抗原阳性的患者清除了HBs Ag,其中1例转为抗-HBs阳性。在仍为HBs Ag阳性的患者中,仅有1例HBe抗原消失,但未出现抗-HBe。在整个研究过程中,与对照组相比,乙肝病毒携带者的谷草转氨酶(SGOT)和谷丙转氨酶(SGPT)水平显著升高。在HBs Ag阳性组中,HBe抗原和/或DNA聚合酶的存在表明该亚组患者的酶水平异常最为显著。HBs Ag阳性组的死亡原因与肝脏疾病无关。病毒复制通常发生在乙肝病毒携带状态,而潜在的肝脏疾病目前并非慢性血液透析患者的主要问题。